<DOC>
	<DOCNO>NCT01445782</DOCNO>
	<brief_summary>This study investigate safety tolerability AZD2115 follow administration multiple ascend dos .</brief_summary>
	<brief_title>AZD2115 Multiple Ascending Dose Study</brief_title>
	<detailed_description>A Phase I , Single Centre , Double-blind , Randomised , Placebo-controlled , Parallel-group Study Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Ascending Inhaled Doses AZD2115 Healthy Male Subjects .</detailed_description>
	<criteria>Healthy male subject age 18 45 year suitable vein cannulation repeat venepuncture Male subject willing use barrier contraception ie , condom spermicide , day first administration AZD2115 3 month administration must donate sperm 3 month followup Have body mass index ( BMI ) 18 30 kg/m2 weigh least 50 kg 100 kg Abnormal vital sign , 10 minute supine rest , define follow : Systolic BP &gt; 140 mmHg Diastolic BP &gt; 90 mmHg Heart rate &lt; 40 &gt; 85 bpm Prolonged QTcF &gt; 450 m shorten QTcF &lt; 340 m family history long QT syndrome Serum potassium concentration &lt; 3.80 mmol/L admission ( Day 1 ) History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge investigator history hypersensitivity drug class AZD2115 excipients History presence gastrointestinal , pulmonary , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>healthy</keyword>
	<keyword>inhale</keyword>
</DOC>